Extended spectrum of antibiotic susceptibility for tuberculosis, Djibouti

Int J Antimicrob Agents. 2018 Feb;51(2):235-238. doi: 10.1016/j.ijantimicag.2017.07.007. Epub 2017 Jul 12.

Abstract

In the Horn of Africa, there is a high prevalence of tuberculosis that is reported to be partly driven by multidrug-resistant (MDR) Mycobacterium tuberculosis strictu sensu strains. We conducted a prospective study to investigate M. tuberculosis complex species causing tuberculosis in Djibouti, and their in vitro susceptibility to standard anti-tuberculous antibiotics in addition to clofazimine, minocycline, chloramphenicol and sulfadiazine. Among the 118 mycobacteria isolates from 118 successive patients with suspected pulmonary tuberculosis, 111 strains of M. tuberculosis, five Mycobacterium canettii, one 'Mycobacterium simulans' and one Mycobacterium kansasii were identified. Drug-susceptibility tests performed on the first 78 isolates yielded nine MDR M. tuberculosis isolates. All isolates were fully susceptible to clofazimine, minocycline and chloramphenicol, and 75 of 78 isolates were susceptible to sulfadiazine. In the Horn of Africa, patients with confirmed pulmonary tuberculosis caused by an in vitro susceptible strain may benefit from anti-leprosy drugs, sulfamides and phenicol antibiotics.

Keywords: Horn of Africa; Mycobacterium canettii; Mycobacterium kansasii; Mycobacterium tuberculosis; ‘Mycobacterium simulans’.

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use*
  • Chloramphenicol / pharmacology
  • Clofazimine / pharmacology
  • Djibouti
  • Female
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Minocycline / pharmacology
  • Mycobacterium kansasii / drug effects*
  • Mycobacterium kansasii / isolation & purification
  • Mycobacterium tuberculosis / classification
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / isolation & purification
  • Prospective Studies
  • Sulfadiazine / pharmacology
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / microbiology
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / microbiology

Substances

  • Antitubercular Agents
  • Sulfadiazine
  • Chloramphenicol
  • Clofazimine
  • Minocycline